Physician profile
Michael A Albritton
NPI 1548264971
$2,317.95
in general payments reported to CMS, 2019-2025
36 companies · $767 in 2025
The $767 reported for 2025 was more than what 80% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.98 · 2020: $58.04 · 2021: $76.13 · 2022: $132 · 2023: $374 · 2024: $821 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,961.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $236.15 | 2023-2025 | Tecvayli, Talvey, Darzalex |
| Novartis Pharmaceuticals Corporation | $181.90 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $177.39 | 2021-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $164.08 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Daiichi Sankyo INC. | $137.29 | 2024-2025 | Enhertu, Injectafer |
| Jazz Pharmaceuticals INC. | $121.39 | 2023-2025 | |
| Genzyme Corporation | $108.21 | 2023-2025 | |
| Incyte Corporation | $103.01 | 2022-2025 | Monjuvi, Jakafi, Niktimvo |
| Progenics Pharmaceuticals, INC. | $97.29 | 2023 | Pylarify |
| Eisai INC. | $94.06 | 2022-2024 | |
| Pharmacosmos Therapeutics INC. | $81.63 | 2024-2025 | Monoferric |
| Genentech USA, INC. | $80.82 | 2023-2025 | Tecentriq, Columvi, Polivy |
| Karyopharm Therapeutics INC. | $65.74 | 2024-2025 | Xpovio |
| Sobi, INC | $56.52 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.80 | 2020-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $48.08 | 2024-2025 | Fruzaqla, Ninlaro |
| Sumitomo Pharma America, INC. | $47.52 | 2024 | Orgovyx |
| Astellas Pharma US INC | $46.47 | 2022-2024 | Xtandi |
| Lilly USA, LLC | $38.08 | 2023-2024 | Verzenio, Jaypirca |
| Tersera Therapeutics LLC | $37.92 | 2021-2022 | |
| Stemline Therapeutics INC. | $34.42 | 2023-2024 | Orserdu |
| Seagen INC. | $29.63 | 2023 | Tukysa |
| Abbvie INC. | $29.27 | 2022 | |
| Exelixis INC. | $28.19 | 2025 | Cabometyx |
| Adaptive Biotechnologies Corporation | $27.43 | 2021-2022 | |
| Blue Earth Diagnostics | $21.92 | 2019 | |
| Dendreon Pharmaceuticals LLC | $20.63 | 2024 | Provenge |
| Angiodynamics, INC. | $20.35 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $20.29 | 2025 | Libtayo |
| Caris Mpi, INC. | $19.27 | 2025 | Mi Cancer Seek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.30 | 2025 | |
| Puma Biotechnology, INC. | $16.23 | 2025 | |
| Pfizer INC. | $14.31 | 2023 | |
| Servier Pharmaceuticals LLC | $14.22 | 2024 | |
| Tolmar, INC. | $13.90 | 2024 | |
| Amgen INC. | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Albritton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.